Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry Diamond

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Evidence-Based Medicine|May 27, 2017
Criticisms of the VAPOUR trial in a recent commentary are unsubstantiated and incorrectWilliam Clark, Paul Bird, Terry Diamond, et al.
The Australasian Journal of Dermatology|February 13, 2003
Androgenetic alopecia in a postmenopausal woman as a result of ovarian hyperthecosisYoungjin Kim, Veli-Matti Marjoniemi, Terry Diamond, et al.
Australian Family Physician|December 9, 2004
Guidelines for the management of postmenopausal osteoporosis for GPsSheila O'Neill, Alastair MacLennan, Shona Bass, et al.
Australian Family Physician|October 31, 2002
Guidelines for the treatment of postmenopausal osteoporosis for general practitionersSheila O'Neill, Philip Sambrook, Terry Diamond, et al.
The Lancet. Oncology|December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trialJames W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology|August 19, 2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trialJames W Denham, David Joseph, David S Lamb, et al.
BJU International|February 12, 2014
Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancerJames W Denham, Michael Nowitz, David Joseph, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Evidence-Based Medicine|May 27, 2017
Criticisms of the VAPOUR trial in a recent commentary are unsubstantiated and incorrectWilliam Clark, Paul Bird, Terry Diamond, et al.
The Australasian Journal of Dermatology|February 13, 2003
Androgenetic alopecia in a postmenopausal woman as a result of ovarian hyperthecosisYoungjin Kim, Veli-Matti Marjoniemi, Terry Diamond, et al.
Australian Family Physician|December 9, 2004
Guidelines for the management of postmenopausal osteoporosis for GPsSheila O'Neill, Alastair MacLennan, Shona Bass, et al.
Australian Family Physician|October 31, 2002
Guidelines for the treatment of postmenopausal osteoporosis for general practitionersSheila O'Neill, Philip Sambrook, Terry Diamond, et al.
The Lancet. Oncology|December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trialJames W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology|August 19, 2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trialJames W Denham, David Joseph, David S Lamb, et al.
BJU International|February 12, 2014
Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancerJames W Denham, Michael Nowitz, David Joseph, et al.
Pageof 2